Synergistic antitumor effect of histone deacetylase class IIa inhibitor with lenvatinib in hepatocellular carcinoma.

Ryo ItoKoji MiyanishiTomohiro KuboKota HamaguchiTakahiro OsugaShingo TanakaHiroyuki OhnumaKazuyuki MuraseKohichi TakadaMinoru NagayamaYasutoshi KimuraToru MizuguchiIchiro TakemasaJunji Kato

Published in: Hepatology international (2023)

Class IIa HDACI and lenvatinib combination therapy induces apoptosis by downregulating FGFR4 and blocking the FGFR signaling in FGFR4-positive HCC cell lines and has demonstrated synergistic antitumor effects and safety. This combination therapy overcomes the problems of conventional therapies and will be beneficial for FGFR4-positive HCC patients.

Keyphrases

combination therapy
histone deacetylase
end stage renal disease
ejection fraction
newly diagnosed
mental health
prognostic factors
peritoneal dialysis